Literature DB >> 18976093

Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats.

H Mischa Zuijdendorp1, Xander Smit, Joleen H Blok, Jean Pierre Caruelle, Denis Barritault, Steven E R Hovius, Johan W van Neck.   

Abstract

OBJECT: Extradural and intraneural scar formation after peripheral nerve injury frequently causes tethering and compression of the nerve as well as inhibition of axonal regeneration. Regenerating agents (RGTAs) mimic stabilizing and protective properties of sulphated glycosaminoglycan toward heparin-binding growth factors. The aim of this study was to assess the effect of an RGTA known as OTR4120 on extraneural fibrosis and axonal regeneration after crush injury in a rat sciatic nerve model.
METHODS: Thirty-two female Wistar rats underwent a standardized crush injury of the sciatic nerve. The animals were randomly allocated to RGTA treatment or sham treatment in a blinded design. To score neural adhesions, the force required to break the adhesions between the nerve and its surrounding tissue was measured 6 weeks after nerve crush injury. To assess axonal regeneration, magnetoneurographic measurements were performed after 5 weeks. Static footprint analysis was performed preoperatively and at Days 1, 7, 14, 17, 21, 24, 28, 35, and 42 postoperatively.
RESULTS: The magnetoneurographic data show no significant difference in conduction capacity between the RGTA and the control group. In addition, results of the static footprint analysis demonstrate no improved or accelerated recovery pattern. However, the mean pullout force of the RGTA group (67 +/- 9 g [mean +/- standard error of the mean]) was significantly (p < 0.001) lower than that of the control group (207 +/- 14 g [mean +/- standard error of the mean]).
CONCLUSIONS: The RGTAs strongly reduce nerve adherence to surrounding tissue after nerve crush injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976093     DOI: 10.3171/JNS/2008/109/11/0967

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

Review 1.  Stewart-Bluefarb syndrome: review of the literature and case report of chronic ulcer treatment with heparan sulphate (Cacipliq20®).

Authors:  Shady Hayek; Bishara Atiyeh; Elias Zgheib
Journal:  Int Wound J       Date:  2013-04-05       Impact factor: 3.315

2.  Refractory sickle cell leg ulcer: is heparan sulphate a new hope?

Authors:  Shady Hayek; Saad Dibo; Joe Baroud; Amir Ibrahim; Denis Barritault
Journal:  Int Wound J       Date:  2014-02-21       Impact factor: 3.315

3.  Diabetes-impaired wound healing is improved by matrix therapy with heparan sulfate glycosaminoglycan mimetic OTR4120 in rats.

Authors:  Miao Tong; Bastiaan Tuk; Peng Shang; Ineke M Hekking; Esther M G Fijneman; Marnix Guijt; Steven E R Hovius; Johan W van Neck
Journal:  Diabetes       Date:  2012-06-20       Impact factor: 9.461

Review 4.  RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients.

Authors:  Denis Barritault; Marie Gilbert-Sirieix; Kim Lee Rice; Fernando Siñeriz; Dulce Papy-Garcia; Christophe Baudouin; Pascal Desgranges; Gilbert Zakine; Jean-Louis Saffar; Johan van Neck
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

5.  A novel experimental rat model of peripheral nerve scarring that reliably mimics post-surgical complications and recurring adhesions.

Authors:  Angela Lemke; Carina Penzenstadler; James Ferguson; Dominika Lidinsky; Rudolf Hopf; Monika Bradl; Heinz Redl; Susanne Wolbank; Thomas Hausner
Journal:  Dis Model Mech       Date:  2017-05-26       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.